Rheumatology Advisor4d
Povorcitinib Improves Hidradenitis Suppurativa in Two Phase 3 Trials
Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.
Managed Healthcare Executive5d
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
AFP1d
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...
The Pharma Letter6d
The week in pharma: action, reaction and insight – week to March 21
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...
Incyte price target lowered to $65 from $69 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...
MyChesCo on MSN6d
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment
Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...
Labiotech.eu3d
A guide to kinase inhibitors in biotech: From cancer breakthroughs to autoimmune innovations
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
pharmaphorum4d
Incyte’s oral vitiligo drug heading for phase 3
New drug candidate povorcitinib is a selective JAK1 inhibitor, given as a once-daily oral dose, which is intended to treat patients with more extensive forms of non-segmental vitiligo - the most ...